← Back to Search

Combination Therapy

tim-brim-dor-bim; full dose lat dor-tim for Open-Angle Glaucoma

Phase 4
Recruiting
Led By Peter E Libre, MD
Research Sponsored by CT Glaucoma Associates
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 weeks after each phase
Awards & highlights

Study Summary

"This trial will compare the effects of using half the normal dose of latanoprost dorzolamide-timolol with the full dose. It will also compare the combination of timolol

Who is the study for?
This trial is for individuals with glaucoma, including open-angle type. Specific eligibility details are not provided, but typically participants would need to meet certain health criteria and not have conditions that could interfere with the study or pose a risk.Check my eligibility
What is being tested?
The trial is testing if half-doses of latanoprost combined with dorzolamide-timolol can manage eye pressure as effectively as full doses. It also compares these treatments to another combination: timolol-brimonidine-dorzolamide-bimatoprost.See study design
What are the potential side effects?
Potential side effects may include dry eyes and other common reactions to glaucoma medications such as redness, discomfort, blurred vision, eyelash growth changes, or darkening of the iris.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 weeks after each phase
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 weeks after each phase for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
intraocular pressure
Secondary outcome measures
dry eye

Trial Design

2Treatment groups
Active Control
Group I: tim-brim-dor-bim; full dose lat dor-timActive Control1 Intervention
After baseline IOP measurements, subjects in this arm will use timolol-brimonidine-dorzolamide-bimatoprost in phase 2, and then full dose latanoprost and dorzolamide-timolol in phase 3.
Group II: full dose lat dor-tim; tim-brim-dor-bimActive Control1 Intervention
After baseline IOP measurements, subjects in this arm will use the full dose full dose latanoprost and dorzolamide-timolol in phase 2, and then timolol-brimonidine-dorzolamide-bimatoprost in phase 3.

Find a Location

Who is running the clinical trial?

CT Glaucoma AssociatesLead Sponsor
Peter E Libre, MDPrincipal InvestigatorCT Glaucoma Associates
~20 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top